Curative Biosciences, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CBDX research report →
Companycurativebio.com
Curative Biosciences, Inc. focuses on developing and commercializing therapeutics using hemp-derived Cannabidiol. It intends to manufacture and market natural health products and operate in the medical cannabis industry.
- CEO
- Katherine T. Alverson West
- IPO
- 2004
- Employees
- 6
- HQ
- Miami, FL, US
Price Chart
Valuation
- Market Cap
- $25.79K
- P/E
- -0.03
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -1.76
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 8.54%
- ROIC
- 9.37%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-53,195 · 96.79%
- EPS
- $-0.00 · 97.17%
- Op Income
- $-53,200
- FCF YoY
- 55.88%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 64.72
- Avg Volume
- 1.97K
Get TickerSpark's AI analysis on CBDX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CBDX Coverage
We haven't published any research on CBDX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CBDX Report →